Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.
Levine
Glenn N
GN
Michael E. DeBakey Veteran's Affairs Medical Center, Houston, TX, USA. glenn.levine@bcm.tmc.edu
D'Amico
Anthony V
AV
Berger
Peter
P
Clark
Peter E
PE
Eckel
Robert H
RH
Keating
Nancy L
NL
Milani
Richard V
RV
Sagalowsky
Arthur I
AI
Smith
Matthew R
MR
Zakai
Neil
N
D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000453:epidemiology / Q000401:mortality; D006801:Humans; D008297:Male; D009017:Morbidity; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D018570:Risk Assessment; D012307:Risk Factors; D014481:United States / Q000453:epidemiology
D000726:Androgen Antagonists; D000970:Antineoplastic Agents